Targeted drug delivery in cancer using nanomaterials: advances and challenges
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Greten FR, Grivennikov SI (2019) Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 51(1):27–4110.1016/j.immuni.2019.06.025 ↗
2. van Weverwijk A, de Visser KE (2023) Mechanisms driving the immunoregulatory function of cancer cells. Nat Rev Cancer 23(4):193–21510.1038/s41568-022-00544-4 ↗
3. Senapati S, Mahanta AK, Kumar S, Maiti P (2018) Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther 3(1):710.1038/s41392-017-0004-3 ↗
4. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A (2020) Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci 7:19310.3389/fmolb.2020.00193 ↗
5. Moyo AA, Jagadhane KS, Bhosale SR, Shinde SB, Marealle AI, Shimpale VB, Anbhule PV (2023) Anbhule, anticancer and apoptotic effects of Hymenodictyon floribundum (Hochst. & Steud.) BL Rob. Stem Bark Hydroethanolic Extract. J Chemistry Africa 7(3):1235–125010.1007/s42250-023-00810-4 ↗
6. Mudgil M, Gupta N, Nagpal M, Pawar P (2012) Nanotechnology: a new approach for ocular drug delivery system. Int J Pharm Pharm Sci 4(2):105–112
7. Thakor AS, Gambhir SS (2013) Nanooncology: the future of cancer diagnosis and therapy. Ca: Cancer J Clinicians 63(6):395–418
8. Bhosale SR, Bhosale RR, Patil DN, Dhavale RP, Kolekar GB, Shimpale VB, Anbhule PV (2023) Bioderived mesoporous carbon@ tungsten oxide nanocomposite as a drug carrier vehicle of doxorubicin for potent cancer therapy. J Langmuir 39(33):11910–1192410.1021/acs.langmuir.3c01715 ↗
9. Bhattacharya T, Soares GABE, Chopra H, Rahman MM, Hasan Z, Swain SS, Cavalu S (2022) Applications of phyto-nanotechnology for the treatment of neurodegenerative disorders. J Materials 15(3):80410.3390/ma15030804 ↗
10. Jin C, Wang K, Oppong-Gyebi A, Hu J (2020) Application of nanotechnology in cancer diagnosis and therapy-a mini-review. Int J Med Sci 17(18):296410.7150/ijms.49801 ↗
11. Mosleh-Shirazi S, Abbasi M, Reza Moaddeli M, Vaez A, Shafiee M, Kasaee SR, Amani AM, Hatam S (2022) Nanotechnology advances in the detection and treatment of cancer: an overview. Nanotheranostics 6(4):40010.7150/ntno.74613 ↗
12. Kemp JA, Kwon YJ (2021) Cancer nanotechnology: current status and perspectives. Nano convergence 8(1):3410.1186/s40580-021-00282-7 ↗
13. Hsieh CY, Ko PW, Chang YJ, Kapoor M, Liang YC, Lin HH, Horng JC, Hsu MH (2019) Design and synthesis of benzimidazole-chalcone derivatives as potential anticancer agents. Molecules 24(18):325910.3390/molecules24183259 ↗
14. Fulton MD, Najahi-Missaoui W (2023) Liposomes in cancer therapy: how did we start and where are we now. Int J Mol Sci 24(7):661510.3390/ijms24076615 ↗
15. Allahou LW, Madani SY, Seifalian A (2021) Investigating the application of liposomes as drug delivery systems for the diagnosis and treatment of cancer. Int J Biomater 2021:304196910.1155/2021/3041969 ↗
16. S. Wadhwa,R.J. Mumper, Polymer-drug conjugates for anticancer drug delivery. Critical Reviews™ in Therapeutic Drug Carrier Systems, 2015. 32(3)10.1615/CritRevTherDrugCarrierSyst.2015010174 ↗
17. Alven S, Nqoro X, Buyana B, Aderibigbe BA (2020) Polymer-drug conjugate, a potential therapeutic to combat breast and lung cancer. Pharmaceutics 12(5):40610.3390/pharmaceutics12050406 ↗
18. Petrilli R, Pinheiro DP, de Cássia Evangelista F, de Oliveira GF, Galvão LG, Marques RFV, Lopez C, Pessoa J.O. Eloy (2021) Immunoconjugates for cancer targeting: a review of antibody-drug conjugates and antibody-functionalized nanoparticles. Curr Med Chem 28(13):2485–252010.2174/0929867327666200525161359 ↗
19. Smaglo BG, Aldeghaither D, Weiner LM (2014) The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol 11(11):637–64810.1038/nrclinonc.2014.159 ↗
20. Bhardwaj K, Sharma A, Kumar R, Tyagi V, Kumar R (2023) Improving oral bioavailability of herbal drugs: a focused review of self-emulsifying drug delivery system for colon cancer. Current Drug Delivery 21(3):389–40210.2174/1567201820666230505113108 ↗
21. Sharma T, Jain A, Kaur R, Saini S, Katare O, Singh B (2020) Supersaturated LFCS type III self-emulsifying delivery systems of sorafenib tosylate with improved biopharmaceutical performance: QbD-enabled development and evaluation. Drug Deliv Transl Res 10:839–86110.1007/s13346-020-00772-x ↗
22. Yu J, Qiu H, Yin S, Wang H, Li Y (2021) Polymeric drug delivery system based on pluronics for cancer treatment. Molecules 26(12):361010.3390/molecules26123610 ↗
23. Sung YK, Kim SW (2020) Recent advances in polymeric drug delivery systems. Biomaterials Research 24(1):1–1210.1186/s40824-019-0177-7 ↗
24. Mukherjee S, Mukherjee S, Abourehab MA, Sahebkar A, Kesharwani P (2022) Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy. Eur Polym J 177:11147110.1016/j.eurpolymj.2022.111471 ↗
25. Nanjwade BK, Bechra HM, Derkar GK, Manvi F, Nanjwade VK (2009) Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci 38(3):185–19610.1016/j.ejps.2009.07.008 ↗
26. Ateeq H, Zia A, Husain Q, Khan MS (2023) Role of inorganic nanocomposite materials in drug delivery systems. synthesis and applications of nanomaterials and nanocomposites. Springer, pp 171–19510.1007/978-981-99-1350-3_7 ↗
27. Zhao C, Rehman FU, Shaikh S, Sajid Z, Mian AA, He N (2022) Metallic nanoscale-knife application in cancer theranostics. Smart Mater Med 4:313–33610.1016/j.smaim.2022.11.006 ↗
28. Liu Q, Zou J, Chen Z, He W, Wu W (2023) Current research trends of nanomedicines. J Acta Pharmaceutica Sinica B 13(11):4391–441610.1016/j.apsb.2023.05.018 ↗
29. Mukherjee A, Bisht B, Dutta S, Paul MK (2022) Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy. Acta Pharmacol Sin 43(11):2759–2776. https://doi.org/10.1038/s41401-022-00902-w10.1038/s41401-022-00902-w ↗
30. Onzi G, Guterres SS, Pohlmann AR, Frank LA (2021) Passive Targeting and the enhanced permeability and retention (EPR) effect. the ADME encyclopedia: a comprehensive guide on biopharmacy and pharmacokinetics. Springer International Publishing, Cham, pp 1–13
31. Nag OK, Awasthi VJP (2013) Surface engineering of liposomes for stealth behavior 5(4):542–569
32. Mishra V, Bansal KK, Verma A, Yadav N, Thakur S, Sudhakar K, Rosenholm JMJP (2018) Solid lipid nanoparticles: emerging colloidal nano drug delivery systems 10(4):191
33. Akanda M, Getti G, Nandi U, Mithu MS, Douroumis D (2021) Bioconjugated solid lipid nanoparticles (SLNs) for targeted prostate cancer therapy. Int J Pharm 599:12041610.1016/j.ijpharm.2021.120416 ↗
34. Jampílek J, Kráľová KJNIB (2019) Recent advances in lipid nanocarriers applicable in the fight against cancer. Nanoarchitectonics in Biomedicine 599:219–29410.1016/B978-0-12-816200-2.00009-8 ↗
35. Maji I, Mahajan S, Sriram A, Medtiya P, Vasave R, Khatri DK, Kumar R, Singh SB, Madan J, Singh PK (2021) Solid self emulsifying drug delivery system: Superior mode for oral delivery of hydrophobic cargos. J Control Release 337:646–66010.1016/j.jconrel.2021.08.013 ↗
36. Giarra S, Lupo N, Campani V, Carotenuto A, Mayol L, De Rosa G, Bernkop-Schnürch A (2019) In vitro evaluation of tumor targeting ability of a parenteral enoxaparin-coated self-emulsifying drug delivery system. J. Drug Delivery Sci Technol 53:101144. https://doi.org/10.1016/j.jddst.2019.10114410.1016/j.jddst.2019.101144 ↗
37. Zhang D, Liu L, Wang J, Zhang H, ZhangZ, Xing G, Wang X, Liu M (2022) Drug-loaded PEG-PLGA nanoparticles for cancer treatment. Front Pharmacol 13:99050510.3389/fphar.2022.990505 ↗
38. Zhang Y, Chen Q, Zhu Y, Pei M, Wang K, Qu X, Zhang Y, Gao J, Qin H (2022) Targeting inorganic nanoparticles to tumors using biological membrane-coated technology. MedComm 3(4):2688–266310.1002/mco2.192 ↗
39. Kunde SS, Wairkar S (2021) Platelet membrane camouflaged nanoparticles: Biomimetic architecture for targeted therapy. Int J Pharm 598:120395. https://doi.org/10.1016/j.ijpharm.2021.12039510.1016/j.ijpharm.2021.120395 ↗
40. Pattni BS, Torchilin VP (2015) Targeted drug delivery systems: strategies and challenges. In: Devarajan P, Jain S (eds) Targeted drug delivery: concepts and design. Advances in Delivery Science and Technology. Springer.10.1007/978-3-319-11355-5_1 ↗
41. Hossen S, Hossain MK, Basher M, Mia M, Rahman M, Uddin MJ (2019) Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review. J Adv Res 15:1–1810.1016/j.jare.2018.06.005 ↗
42. Kumar A, Behl T, Chadha S (2020) Synthesis of physically crosslinked PVA/Chitosan loaded silver nanoparticles hydrogels with tunable mechanical properties and antibacterial effects. J Int J Biol Macromolecules 149:1262–127410.1016/j.ijbiomac.2020.02.048 ↗
43. Kaur N, Popli P, Tiwary N, Swami R (2023) Small molecules as cancer targeting ligands: shifting the paradigm. J Control Release 355:417–43310.1016/j.jconrel.2023.01.032 ↗
44. Tiwari H, Rai N, Singh S, Gupta P, Verma A, Singh AK, Kajal P, Salvi SK, Singh V (2023) Gautam, Recent advances in nanomaterials-based targeted drug delivery for preclinical cancer diagnosis and therapeutics. Bioengineering 10(7):76010.3390/bioengineering10070760 ↗
45. Yoo J, Park C, Yi G, Lee D, Koo H (2019) Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers 11(5):64010.3390/cancers11050640 ↗
46. Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P (2020) Tumor microenvironment complexity and therapeutic implications at a glance. Cell Communication and Signaling 18:1–1910.1186/s12964-020-0530-4 ↗
47. Lugano R, Ramachandran M, Dimberg A (2020) Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 77:1745–177010.1007/s00018-019-03351-7 ↗
48. Wei Q-Y, Xu Y-M, Lau AT (2020) Recent progress of nanocarrier-based therapy for solid malignancies. Cancers 12(10):278310.3390/cancers12102783 ↗
49. Ejigah V, Owoseni O, Bataille-Backer P, Ogundipe OD, Fisusi FA, Adesina SK (2022) Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect. Polymers 14(13):260110.3390/polym14132601 ↗
50. Hirsjarvi S, Passirani C, Benoit J-P (2011) Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol 8(3):188–19610.2174/157016311796798991 ↗
51. Bhargav AG, Mondal SK, Garcia CA, Green JJ, Quiñones-Hinojosa A (2020) Nanomedicine revisited: next generation therapies for brain cancer. Advanced Therapeutics 3(10):200011810.1002/adtp.202000118 ↗
52. Vyas SP, Singh A, Sihorkar V (2001) Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. Critical Reviews™ in Therapeutic Drug Carrier Systems 18(1):1–7610.1615/CritRevTherDrugCarrierSyst.v18.i1.10 ↗
53. Tietjen GT, Bracaglia LG, Saltzman WM, Pober JS (2018) Focus on fundamentals: achieving effective nanoparticle targeting. Trends Mol Med 24(7):598–60610.1016/j.molmed.2018.05.003 ↗
54. Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb A (2017) Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine 12:7291–730910.2147/IJN.S146315 ↗
55. Lu R-M, Hwang Y-C, Liu I-J, Lee C-C, Tsai H-Z, Li H-J, Wu H-C (2020) Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci 27(1):1–3010.1186/s12929-019-0592-z ↗
56. Zahavi D, Weiner L (2020) Monoclonal antibodies in cancer therapy. Antibodies 9(3):3410.3390/antib9030034 ↗
57. Glennie MJ, Johnson PW (2000) Clinical trials of antibody therapy. Immunol Today 21(8):403–41010.1016/S0167-5699(00)01669-8 ↗
58. Chen L, Hong W, Ren W, Xu T, Qian Z, He Z (2021) Recent progress in targeted delivery vectors based on biomimetic nanoparticles. Signal Transduct Target Ther 6(1):22510.1038/s41392-021-00631-2 ↗
59. Alley SC, Okeley NM, Senter PD (2010) Antibody–drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 14(4):529–53710.1016/j.cbpa.2010.06.170 ↗
60. Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y (2020) The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol 11:195110.3389/fimmu.2020.01951 ↗
61. Shepard HM, Phillips GL, Thanos CD, Feldmann M (2017) Developments in therapy with monoclonal antibodies and related proteins. Clin Med 17(3):22010.7861/clinmedicine.17-3-220 ↗
62. Pillay V, Gan HK, Scott AM (2011) Antibodies in oncology. New Biotechnol 28(5):518–52910.1016/j.nbt.2011.03.021 ↗
63. Ahmad NA, Zulkifli RM, Hussin H, Nadri MH (2021) In silico approach for Post-SELEX DNA aptamers: a mini-review. J Mol Graph Model 105:10787210.1016/j.jmgm.2021.107872 ↗
64. Chen K, Liu B, Yu B, Zhong W, Lu Y, Zhang J, Liao J, Liu J, Pu Y, Qiu L (2017) Advances in the development of aptamer drug conjugates for targeted drug delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 9(3):e1438
65. Gao F, Yin J, Chen Y, Guo C, Hu H, Su J (2022) Recent advances in aptamer-based targeted drug delivery systems for cancer therapy. Front Bioeng Biotechnol 10:97293310.3389/fbioe.2022.972933 ↗
66. Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y (2014) Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids 3:E18210.1038/mtna.2014.32 ↗
67. Hasegawa H, Savory N, Abe K, Ikebukuro K (2016) Methods for improving aptamer binding affinity. Molecules 21(4):42110.3390/molecules21040421 ↗
68. Hu X, Tang L, Zheng M, Liu J, Zhang Z, Li Z, Yang Q, Xiang S, Fang L, Ren Q (2022) Structure-guided designing pre-organization in bivalent aptamers. J Am Chem Soc 144(10):4507–451410.1021/jacs.1c12593 ↗
69. Zhong Y, Meng F, Deng C, Zhong Z (2014) Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromol 15(6):1955–196910.1021/bm5003009 ↗
70. Tortorella S, Karagiannis TC (2014) Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J Membr Biol 247:291–30710.1007/s00232-014-9637-0 ↗
71. Dosio F, Arpicco S, Stella B, Fattal E (2016) Hyaluronic acid for anticancer drug and nucleic acid delivery. Adv Drug Deliv Rev 97:204–23610.1016/j.addr.2015.11.011 ↗
72. Akim A, Zafar MN, Safdar N, Sung YY, Muhammad TST (2021) Understanding hyaluronan receptor (CD44) interaction, HA-CD44 activated potential targets in cancer therapeutics. Advanced Pharmaceutical Bulletin 11(3):426
73. Ebrahimnejad P, Taleghani AS, Asare-Addo K, Nokhodchi A (2022) An updated review of folate-functionalized nanocarriers: a promising ligand in cancer. Drug Discovery Today 27(2):471–48910.1016/j.drudis.2021.11.011 ↗
74. Scaranti M, Cojocaru E, Banerjee S, Banerji U (2020) Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol 17(6):349–35910.1038/s41571-020-0339-5 ↗
75. Mousavizadeh A, Jabbari A, Akrami M, Bardania H (2017) Cell targeting peptides as smart ligands for targeting of therapeutic or diagnostic agents: a systematic review. Colloids Surf, B 158:507–51710.1016/j.colsurfb.2017.07.012 ↗
76. Bhosale RR, Gangadharappa HV, Gowda DV, Osmani RAMA, Vaghela R, Kulkarni PK, Sairam KV, Gurupadayya B (2018) Current perspectives on novel drug carrier systems and therapies for management of pancreatic cancer: an updated inclusive review. Critical Reviews™ in Therapeutic Drug Carrier Systems 35(3):195–29210.1615/CritRevTherDrugCarrierSyst.2018019429 ↗
77. Walker S, Busatto S, Pham A, Tian M, Suh A, Carson K, Quintero A, Lafrence M, Malik H, Santana MX (2019) Extracellular vesicle-based drug delivery systems for cancer treatment. Theranostics 9(26):800110.7150/thno.37097 ↗
78. Wu M, Wang M, Jia H, Wu P (2022) Extracellular vesicles: Emerging anti-cancer drugs and advanced functionalization platforms for cancer therapy. Drug Delivery 29(1):2513–253810.1080/10717544.2022.2104404 ↗
79. Kos J, Obermajer N, Doljak B, Kocbek P, Kristl J (2009) Inactivation of harmful tumour-associated proteolysis by nanoparticulate system. Int J Pharm 381(2):106–112. https://doi.org/10.1016/j.ijpharm.2009.04.03710.1016/j.ijpharm.2009.04.037 ↗
80. Vinothini K, Rajendran NK, Ramu A, Elumalai N, Rajan M (2019) Folate receptor targeted delivery of paclitaxel to breast cancer cells via folic acid conjugated graphene oxide grafted methyl acrylate nanocarrier. Biomed Pharmacother 110:906–917. https://doi.org/10.1016/j.biopha.2018.12.00810.1016/j.biopha.2018.12.008 ↗
81. Taymouri S, Alem M, Varshosaz J, Rostami M, Akbari V, L. (2019) Firoozpour, Biotin decorated sunitinib loaded nanostructured lipid carriers for tumor targeted chemotherapy of lung cancer. J Drug Delivery Sci Technol 50:237–247. https://doi.org/10.1016/j.jddst.2019.01.02410.1016/j.jddst.2019.01.024 ↗
82. Deng X, Cao M, Zhang J, Hu K, Yin Z, Zhou Z, Xiao X, Yang Y, Sheng W, Wu Y, Zeng Y (2014) Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials 35(14):4333–434410.1016/j.biomaterials.2014.02.006 ↗
83. Mashreghi M, Zamani P, Moosavian SA, Jaafari MR (2020) Anti-EpCAM aptamer (Syl3c)-functionalized liposome for targeted delivery of doxorubicin: in vitro and in vivo antitumor studies in mice bearing C26 colon carcinoma. Nanoscale Res Lett 15(1):101. https://doi.org/10.1186/s11671-020-03334-910.1186/s11671-020-03334-9 ↗
84. Bhagwat GS, Athawale RB, Gude RP, Md S, Alhakamy NA, Fahmy UA, Kesharwani P (2020) Formulation and development of transferrin targeted solid lipid nanoparticles for breast cancer therapy. Front Pharmacol 11:61429010.3389/fphar.2020.614290 ↗
85. Kazemi Y, Dehghani S, Soltani F, Abnous K, Alibolandi M, Taghdisi SM, Ramezani M (2022) PNA-ATP aptamer-capped doxorubicin-loaded silica nanoparticles for targeted cancer therapy. Nanomed: Nanotechnol Biol Med 45:102588. https://doi.org/10.1016/j.nano.2022.10258810.1016/j.nano.2022.102588 ↗
86. Moon Y, Shim MK, Choi J, Yang S, Kim J, Yun WS, Cho H, Park JY, Kim Y, Seong JK, Kim K (2022) Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death. Theranostics 12(5):1838–764010.7150/thno.69119 ↗
87. Liu W, Su J, Shi Q, Wang J, Chen X, Zhang S, Li M, Cui J, Fan C, Sun B, Wang G (2021) RGD Peptide-conjugated selenium nanocomposite inhibits human glioma growth by triggering mitochondrial dysfunction and ROS-dependent MAPKs activation. Front Bioeng Biotechnol 9:78160810.3389/fbioe.2021.781608 ↗
88. Luo K, Yin S, Zhang R, Yu H, Wang G, Li J (2020) Multifunctional composite nanoparticles based on hyaluronic acid-paclitaxel conjugates for enhanced cancer therapy. Int J Pharm 589:119870. https://doi.org/10.1016/j.ijpharm.2020.11987010.1016/j.ijpharm.2020.119870 ↗
89. Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, Torchilin VP (2021) Recent advances in tumor targeting via EPR effect for cancer treatment. Journal of personalized medicine 11(6):57110.3390/jpm11060571 ↗
90. Nakamura Y, Mochida A, Choyke PL, Kobayashi H (2016) Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug Chem 27(10):2225–223810.1021/acs.bioconjchem.6b00437 ↗
91. Shi J, Kantoff PW, Wooster R, Farokhzad OC (2017) Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 17(1):20–3710.1038/nrc.2016.108 ↗
92. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91(3):1071–112110.1152/physrev.00038.2010 ↗
93. Munir MU (2022) Nanomedicine penetration to tumor: challenges, and advanced strategies to tackle this issue. Cancers 14(12):290410.3390/cancers14122904 ↗
94. Souri M, Soltani M, Kashkooli FM, Shahvandi MK, Chiani M, Shariati FS, Mehrabi MR, Munn LL (2022) Towards principled design of cancer nanomedicine to accelerate clinical translation. Materials Today Bio 13:10020810.1016/j.mtbio.2022.100208 ↗
95. Mahmood J, Alexander AA, Samanta S, Kamlapurkar S, Singh P, Saeed A, Carrier F, Cao X, Shukla HD, Vujaskovic Z (2020) A combination of radiotherapy, hyperthermia, and immunotherapy inhibits pancreatic tumor growth and prolongs the survival of mice. Cancers 12(4):101510.3390/cancers12041015 ↗
96. Bae YH, Park K (2011) Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 153(3):198–20510.1016/j.jconrel.2011.06.001 ↗
97. Ferretti S, Allegrini PR, Becquet MM, McSheehy PM (2009) Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics. Neoplasia 11(9):874–88110.1593/neo.09554 ↗
98. Holback H, Yeo Y (2011) Intratumoral drug delivery with nanoparticulate carriers. Pharm Res 28:1819–183010.1007/s11095-010-0360-y ↗
99. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng H, Pfister SM, Reifenberger G (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–125110.1093/neuonc/noab106 ↗
100. Reagan M (2019) Causes of cancer: Genetic, epigenetic, viral, microenvironmental, and environmental contributions to cancer. In: Cancer, prevention, early detection, treatment and recovery, pp 53–7410.1002/9781119645214.ch3 ↗